In a first, AstraZeneca admits its Covid vaccine can cause rare blood clots
British-Swedish pharma giant’s covid vaccine was widely administered in over 150 countries
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Pharmaceutical giant AstraZeneca has admitted that its widely used Covid vaccine, branded Covishield, can cause rare side effects including blood clots and low platelet count.
Covishield was developed by the British-Swedish company in collaboration with Oxford University, UK, and produced by the Serum Institute of India. It was widely administered in over 150 countries, including Britain and India.
Some studies conducted during the pandemic found the vaccine was 60 to 80 per cent effective in protecting against the novel coronavirus.
However, research has since found that Covishield can cause some people to develop blood clots, which may prove fatal.
A class action lawsuit filed in the UK claimed that the vaccine led to deaths and severe injuries and sought damages up to £100m for about 50 victims.
One of the complainants alleged that the vaccine caused him a permanent brain injury after he developed a blood clot, preventing him from working.
While AstraZeneca has contested these claims, it admitted for the first time in one of the court documents that the vaccine can “in very rare cases, cause TTS”, or Thrombosis with Thrombocytopenia Syndrome, which is characterised by blood clots and a low blood platelet count in humans.
“It is admitted that the AZ vaccine can, in very rare cases, cause TTS. The causal mechanism is not known,” the company said in the court documents in February, The Telegraph reported.
“Further, TTS can also occur in the absence of the AZ vaccine (or any vaccine). Causation in any individual case will be a matter for expert evidence,” it added.
The admission by AstraZeneca runs counter to the company’s insistence in 2023 that it would “not accept that TTS is caused by the vaccine at a generic level”.
The World Health Organization confirmed that Covishield can have life-threatening side effects. “A very rare adverse event called Thrombosis with Thrombocytopenia Syndrome, involving unusual and severe blood clotting events associated with low platelet counts, has been reported after vaccination with this vaccine.”
According to the Council for International Organizations of Medical Sciences, “very rare” side effects are those reported in less than 1 in 10,000 cases.
“In countries with ongoing SARS-CoV-2 transmission, the benefit of vaccination in protecting against COVID-19 far outweighs the risks,” the WHO added.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments